Akash Mourya | Health and Medicine Advances | Best Researcher Award

Published on by New Scientists

Mr. Akash Mourya | Health and Medicine Advances | Best Researcher Award

PhD Scholar | National Institutes of Pharmaceutical Education and Research | India

Mr. Akash Mourya is a promising young pharmacologist specializing in pharmacology and toxicology, with a strong research focus on liver pathophysiology, hepatoprotective drug discovery, and molecular mechanisms underlying hepatic and pulmonary disorders. His ongoing Ph.D. work at NIPER Mohali builds on extensive preclinical and translational research conducted at the Institute of Liver and Biliary Sciences (ILBS), New Delhi, where he has developed expertise in animal models of liver diseases, hemodynamic studies, and hepatic cell culture systems. His research contributions have advanced understanding of non-alcoholic and alcoholic fatty liver diseases, hepatopulmonary and porto-pulmonary hypertension, and liver regeneration mechanisms. He has co-authored seven peer-reviewed publications in high-impact journals, including Journal of Hepatology, JHEP Reports, American Journal of Physiology–Gastrointestinal and Liver Physiology, npj Gut and Liver, ACS Omega, and Life Sciences. His work has collectively received 31 citations, 7 Documents, with an h-index of 3, reflecting growing recognition within the biomedical research community. In addition to journal articles, Mr. Akash Mourya has contributed two book chapters published by Springer Nature (2024) and Academic Press (2025), covering topics such as oxidative stress and pharmacological interventions in liver disease, and PPARγ signaling in diabetes. His research abstracts have been presented at prestigious international conferences, including the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL). His work integrates pharmacological innovation, molecular biology, and experimental therapeutics, with emphasis on Ayurvedic formulations, CB2 receptor agonists, and novel siRNA nanoparticle delivery systems. Mr. Akash Mourya’s ongoing efforts contribute to translational R&D for liver protection and regeneration, aligning with India’s growing emphasis on integrative pharmacology and precision medicine.

Profiles: Scopus | Google Scholar | ResearchGate | PubMed 

Featured Publications

1. Baweja, S., Kumari, A., Negi, P., Tomar, A., Tripathi, D. M., Mourya, A. K., Rastogi, A., Subudhi, P. D., Thangariyal, S., Kumar, G., Kumar, J., Sood, A., Vashistha, C., Bihari, C., Maiwall, R., & Sarin, S. K. (2023). Hepatopulmonary syndrome is associated with low sphingosine-1-phosphate levels and can be ameliorated by the functional agonist fingolimod. Journal of Hepatology, 79(1), 167–180.

2. Juneja, P., Rahman, S. N. R., Jakhar, D., Mourya, A. K., Tripathi, D. M., Kaur, I., Tiwari, V., & others. (2023). Recombinant VEGF-C (Cys156Ser) improves mesenteric lymphatic drainage and gut immune surveillance in experimental cirrhosis. JHEP Reports, 5(10), 100816.

3. Biswas, S., Yadav, N., Juneja, P., Mourya, A. K., Kaur, S., Tripathi, D. M., & Chauhan, V. S. (2022). Conformationally restricted dipeptide-based nanoparticles for delivery of siRNA in experimental liver cirrhosis. ACS Omega, 7(41), 36811–36824.

4. Kaur, I., Juneja, P., Tiwari, R., Vasudevan, A., Mourya, A. K., Trauner, M., Sarin, S. K., & Tripathi, D. M. (2024). Secondary bile acids in portal blood contribute to liver regeneration in a rat model of partial hepatectomy. American Journal of Physiology – Gastrointestinal and Liver Physiology, 327(4), G645–G658.

5. Tripathi, D. M., Singh, P., Mourya, A. K., & Kaur, S. (2024). Oxidative medicine and novel pharmacological treatment approaches in liver disease. In Adaptation under stressful environments through biological adjustments and interventions (pp. 311–334). Springer Nature.

 

Bing Han | Health and Medicine Advances | Best Researcher Award

Published on by New Scientists

Dr. Bing Han | Health and Medicine Advances | Best Researcher Award

Postdoctoral Researcher, The First Affiliated Hospital of Zhengzhou University, China

Dr. Bing Han, Professor at The First Affiliated Hospital of Zhengzhou University, China, is an accomplished medical scientist and clinician whose research bridges molecular biology, microbiome science and clinical gastroenterology. He earned his medical degree (M.D.) followed by postdoctoral research training focused on digestive disease mechanisms and microbial interactions, establishing a strong foundation in translational and precision medicine. His primary research interests center on the gut microbiota–host interaction, bile acid metabolism, intestinal inflammation and biomarker discovery for digestive disorders, with emerging interests in microbiome-based therapeutic interventions. Over his distinguished career, Dr. Bing Han has held academic and clinical roles at The First Affiliated Hospital of Zhengzhou University and collaborated with The First Affiliated Hospital of the University of Science and Technology of China, contributing to interdisciplinary advancements in medical research. His key scientific contributions include innovative studies on the mechanisms of fecal microbiota transplantation in improving inflammatory bowel disease (IBD) and the development of biomedical devices such as spinal positioning systems and femoral defect fixation stents. He has published 9 scientific documents, receiving 50 citations with an h-index of 5 and authored the academic book Frontiers of Tumor Research. Among his notable research supports are the China Postdoctoral Science Foundation Grant, National Natural Science Foundation of China Grant and the Guangxi Natural Science Foundation and Health Commission Projects of Guangxi Zhuang Autonomous Region. His professional engagements include serving as a Young Editorial Board Member for the Journal of Guangxi Medical University and membership in the Digestive Professional Committee of the Chinese Society of Pathophysiology and the Gut Microbiota Branch of the Chinese Society of Biophysics. Through his pioneering research on gut microbiota and digestive pathophysiology, Dr. Bing Han aims to revolutionize clinical diagnostics and therapeutics, promoting global health advancement and innovation in biomedical science.

Profile: Scopus | ORCID | ResearchGate

Featured Publications

1. Han, B., Tang, D., Zhu, H., et al. (2024). Integrated multi-omics reveal gut microbiota-mediated bile acid metabolism regulating immunotherapy responses to anti-α4β7-integrin in Crohn’s disease. Gut Microbes, 16(1), 2310894.

2. Han, B., Li, C., Meng, H., et al. (2019). Efficacy and safety of external-beam radiation therapy for hepatocellular carcinoma: An overview of current evidence according to the different target population. Bioscience Trends, 13(1), 10–22.

3. Han, B., Tang, D., Lv, X., et al. (2023). Comparative efficacy and safety of combination therapy with infliximab for Crohn’s disease: A systematic review and network meta-analysis. International Journal of Colorectal Disease, 38(1), 82.

4. Han, B., Shao, L., Li, C., et al. (2019). Surgery versus external beam radiation therapy for AJCC stage I hepatocellular carcinoma. Journal of BUON, 24(4), 1390–1401.

5. Han, B., Yao, H., Shao, L., et al. (2018). Selection of treatment modalities for hepatocellular carcinoma at stages T1 and T2: A preliminary analysis based on the Surveillance, Epidemiology, and End Results registry database. Journal of BUON, 23(3), 611–621.

 

Seema Kandalkar | Health and Medicine Advances | Best Researcher Award

Published on by New Scientists

Ms. Seema Kandalkar | Health and Medicine Advances | Best Researcher Award

Student, Sanjivani College of Pharmaceutical Education and Research, Kopargaon (SPPU), India

Ms. Seema Kandalkar is a dedicated pharmaceutical researcher currently serving as an IPR Trainee at Trexo Global Pvt. Ltd, Nashik, and is affiliated with Sanjivani College of Pharmaceutical Education and Research (SPPU). She completed her M. Pharmacy in Pharmaceutics from Sanjivani College of Pharmaceutical Education and Research, Kopargaon, in 2025, following a B. Pharmacy from Pravara Rural Education Society College of Pharmacy (SPPU, 2023). Her research primarily focuses on formulation and development of innovative drug delivery systems, including probiotic and effervescent tablet formulations, with emerging interests in regulatory affairs and intellectual property rights. She has gained significant hands-on experience through her industrial projects and internships at Sci-Tech Efferceuticals (R&D), Sanpras Healthcare Pvt. Ltd., and Reve Pharma, where she honed practical skills in analytical techniques, GMP, stability studies, dissolution testing and drug delivery design. Among her key contributions, she successfully developed and evaluated a probiotic effervescent tablet during her M. Pharmacy project and has disseminated her findings via a review article accepted in Journal of Future Foods (ScienceDirect, IF 7.2), along with poster presentations at international conferences and participation in national-level research competitions. Her work has been recognized for its academic rigor and innovative approach in pharmaceutical sciences, earning accolades through national seminars and competitive workshops. Professionally, she is skilled in Microsoft Office Suite, BioRender and Zotero and actively participates in scientific workshops and seminars. Author metrics for Ms. Seema Kandalkar include 1 published document with citation potential, currently reflecting initial scholarly impact. Her work contributes to advancing formulation science, promoting effective healthcare solutions, and strengthening pharmaceutical innovation and intellectual property awareness. Her vision encompasses enhancing patient-centric drug delivery, fostering regulatory excellence and contributing to global pharmaceutical research standards. With her blend of academic excellence, industrial exposure and research innovation, Ms. Seema Kandalkar is well-positioned to make significant contributions to pharmaceutical sciences and healthcare innovation internationally.

Profile: ORCID | ResearchGate | LinkedIn

Featured Publications

1. Kandalkar, S. T., Shendge, R. S., & Lohakare, O. K. (2025). Unveiling the therapeutic potential of probiotics: A review. Journal of Future Foods. Advance online publication.

 

Paul Padovani | Health and Medicine | Best Researcher Award

Published on by New Scientists

Dr. Paul Padovani | Health and Medicine | Best Researcher Award

Pediatric cardiologist, University Hospital of Nantes, France

Dr. Paul Padovani is a Junior Doctor in Pediatric and Congenital Cardiology (MD, MSc in Clinical Research) at Nantes University Hospital (CHU de Nantes), France, where he integrates clinical practice, research, and digital health innovation to enhance outcomes for children with congenital heart disease. He earned his MD and MSc in Clinical Research, completing specialized cardiovascular medicine training after ranking 372nd in the French National Exam (ECN), with rotations in leading French university hospitals. His research focuses on pediatric and congenital interventional cardiology, quality-of-life assessment and exercise physiology in CHD, simulation-based medical education, and the development of AI/NLP pipelines integrated with OMOP Common Data Model (CDM) to enable structured healthcare data analysis. Professionally, he has contributed to over ten major research projects, including QUALISYSTEMIC, the first nationwide study on systemic right ventricle quality of life, and SIMUL-CHD, a randomized controlled trial on simulation-based communication training, while also leading AI-driven multicenter data initiatives. Dr. Paul Padovani has published 14 peer-reviewed articles, achieving 56 citations and an h-index of 4, reflecting his emerging impact in pediatric cardiology and digital health. He has received competitive research grants and recognition for advancing multicenter clinical studies and digital health programs. He is an active member of the French Society of Pediatric Cardiology (SFCP) and the Association for European Paediatric and Congenital Cardiology (AEPC), participating in international collaborations and peer-reviewed research efforts. His skills encompass clinical trial design, pediatric interventional procedures, simulation-based education, quality-of-life assessments, and AI-enabled data integration. Dr. Paul Padovani’s vision is to bridge clinical innovation, research, and education, improving patient outcomes, fostering reproducible research, and mentoring future leaders. His work is transforming pediatric cardiology, advancing digital health solutions, and establishing him as a globally recognized emerging leader in health and medicine.

Profile: Scopus | ORCID | ResearchGate | Sci Profiles | Scilit | LinkedIn

Featured Publications

1. Padovani, P., Singh, Y., Pass, R. H., Vasile, C. M., Nield, L. E., & Baruteau, A.-E. (2023). E-health: A game changer in fetal and neonatal cardiology? Journal of Clinical Medicine, 12(21), 6865.

2. Vasile, C. M., Padovani, P., Rujinski, S. D., Nicolosu, D., Toma, C., Turcu, A. A., & Cioboata, R. (2023). The increase in childhood obesity and its association with hypertension during pandemics. Journal of Clinical Medicine, 12(18), 5909.

3. Dardari, M., Iorgulescu, C., Bataila, V., Deaconu, A., Cinteza, E., Vatasescu, R., Padovani, P., Vasile, C. M., & Dorobantu, M. (2023). Transvenous lead extraction in a European low-volume center without on-site surgical support. Reports, 6(3), 41.

4. Dardari, M., Cinteza, E., Vasile, C. M., Padovani, P., & Vatasescu, R. (2023). Infective endocarditis among pediatric patients with prosthetic valves and cardiac devices: A review and update of recent emerging diagnostic and management strategies. Journal of Clinical Medicine, 12(15), 4941.

5. Padovani, P., Grunenwald Gronier, C., & Baruteau, A.-E. (2023). Midline crossing right pulmonary veins with dual drainage to the left atrium. Cardiology in the Young, 33(2), 305–308.